Impact ledger
ENDRA Life Sciences Inc. (NDRA): the developments shaping its investment case
Follow the evidence affecting ENDRA Life Sciences Inc.'s valuation assumptions, demand outlook. Review the key developments below. Continue in Market Ontology to test your assumptions, examine related opportunities, and save the investment case you want to track.
Test assumptions, examine opportunities, and save your research.
Material developments
Evidence affecting valuation assumptions
Each entry names the assumption the evidence touches and how the evidence reads. Direction describes the business mechanism, not a stock-price conclusion.
| Date | Assumption | Direction | Interpretation |
|---|---|---|---|
| 2026-07-22 | multiple | Bearish | Incremental float typically compresses near-term multiple absent revenue acceleration. |
| 2026-07-22 | share_count | Bullish | Primary equity issuance increases diluted share count. |
| 2026-06-25 | multiple | Bullish | Target re-rates to bid premium until close. |
| 2026-06-25 | share_count | Bullish | Stock component of consideration dilutes existing acquirer holders. |
| 2026-06-25 | net_debt | Bullish | Cash component of consideration is typically debt-funded, raising net debt. |
| 2026-06-25 | revenue | Bullish | Acquisition adds target revenue to acquirer P&L on close. |
Event impact log
3 events mapped to NDRA since 2026-08-17. Evidence through 2026-08-21.
| Date | Event | Channel | Direction | Horizon | Impact |
|---|---|---|---|---|---|
| 2026-08-21 | ASP Isotopes Inc. to Merge Renergen Asset into ENDRA Life Sciences Inc. | Direct impact from acquiring a new business (Renergen) and a complete strategic pivot. This will fundamentally change NDRA's business model, revenue streams, and risk profile. | mixed | 3-12m | 0.80 |
| 2026-08-21 | ASP Isotopes Inc. to Acquire ENDRA Life Sciences Inc. | Direct impact from acquisition premium and increased certainty of value realization for shareholders. | Bullish | intraday | 0.80 |
| 2026-08-17 | ENDRA Life Sciences Inc. to Acquire Noble Africa LLC | Direct corporate action: acquisition, change in business focus, potential delisting/relisting, and significant dilution for existing shareholders. The company is pivoting from medical devices to natural gas exploration. | mixed | 1-3m | 0.80 |
Continue this research
Build your ENDRA Life Sciences Inc. investment case. Continue from the evidence above, change the assumptions the developments move, and save the work to revisit as the case develops.
This ledger is regenerated from Market Ontology's public event pipeline. View the NDRA entity page →